Status:
UNKNOWN
Escin in Patients With Covid-19 Infection
Lead Sponsor:
University of Catanzaro
Collaborating Sponsors:
Azienda Ospedaliera Pugliese Ciaccio
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Conditions:
Coronavirus Infections
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were inf...
Eligibility Criteria
Inclusion
- Aged between 18 and 75 years, extremes included, male or female
- Positivity to covid-19 screening test in molecular biology
- In escin group: Low response to standard treatment
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Female subjects who are pregnant or breastfeeding.
- patients with previous history to allergy
- patients meet the contraindications of escin
- Patients have any condition that in the judgement of the Investigators would make the subject inappropriate for entry into this study.
- patients can't take drugs orally
Key Trial Info
Start Date :
March 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2020
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04322344
Start Date
March 23 2020
End Date
December 30 2020
Last Update
September 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Luca Gallelli
Catanzaro, Italy, 88100